Back to top

gene-editing: Archive

Zacks Equity Research

SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure

Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.

RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change

Sundeep Ganoria

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

VRTXPositive Net Change BEAMPositive Net Change NTLANegative Net Change CRSPPositive Net Change

Sundeep Ganoria

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?

LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.

NVSPositive Net Change PFEPositive Net Change NVONegative Net Change LLYPositive Net Change

Ekta Bagri

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025

GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

ILMNNegative Net Change BEAMPositive Net Change WVENegative Net Change CRSPPositive Net Change TWSTNegative Net Change WGSPositive Net Change